Home › Markets › Health Care › IMNM

Immunome Inc. (IMNM)

IMNM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$17.58
-8.20% on the day
Market cap
$2.1B
Mid cap
Revenue · 2025
$6.9M
-23.2% on 2024
Net income · 2025
-$212.4M
-3060.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerIMNM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001472012
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$6.9M
Net income-$212.4M
Operating income-$224.1M
Net margin-3060.0%
Operating margin-3228.8%
Revenue growth-23.2%
Cash$653.5M
Total assets$683.2M
P/E (computed)Net income was not positive
P/S (computed)298.9×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-17
Latest annual report10-K2026-03-03
Latest quarterly / interim10-Q2026-08-11
Latest current report8-K2026-10-05
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 459 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-10.0%
1 month-28.3%
3 months-22.6%
Year to date-20.0%
1 year+20.6%
From 52-week high-42.4%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VRDNViridian Therapeutics Inc.$18.22-0.44%$2.1B
PHVSPharvaris N.V.$30.02-2.82%$2.1B
PRGOPerrigo Company plc$15.37-0.52%$2.1B
HRMYHarmony Biosciences Holdings Inc.$37.03-3.14%$2.2B
IRONDisc Medicine Inc.$56.60-6.42%$2.2B
AUPHAurinia Pharmaceuticals Inc$16.36-1.15%$2.2B
BHCBausch Health Companies Inc.$5.89-0.68%$2.2B
SDGRSchrodinger Inc.$25.89-0.08%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier